loading...| Preferred Name |
Ridinilazole |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152212 |
| CAS_Registry |
308362-25-6 |
| code |
C152212 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
A narrow-spectrum antibiotic with potential activity against Clostridioides difficile infection (CDI). Upon oral administration, ridinilazole exerts its bactericidal activity against C. difficile through inhibition of cell division. This suppresses bacterial toxin production and inhibits the associated inflammatory response. Compared to other antibiotics that treat C. difficile, ridinilazole does not deplete intestinal bacteria and preserves the intestinal bacterial activity and the associated bile acid metabolome. |
| Display_Name |
Ridinilazole |
| FDA_UNII_Code |
06DX01190R |
| FULL_SYN |
Ridinilazole RIDINILAZOLE WHO 10075 5,5'-Bi-1H-benzimidazole, 2,2'-Di-4-pyridinyl- SMT19969 SMT-19969 |
| label |
Ridinilazole |
| NCI_META_CUI |
CL553416 |
| Preferred_Name |
Ridinilazole |
| prefixIRI |
Thesaurus:C152212 |
| prefLabel |
Ridinilazole |
| Semantic_Type |
Pharmacologic Substance Antibiotic |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| http://purl.bioontology.org/ontology/MESH/C000601750 | Medical Subject Headings / 医学主题词表 | LOOM |